Provectus Biopharmaceuticals Inc (PVCT)

0.13
0.12 47.00
AMEX : Health Care
Prev Close 0.25
Open 0.23
Day Low/High 0.09 / 0.23
52 Wk Low/High 0.18 / 0.70
Volume 16.18M
Avg Volume 368.50K
Exchange AMEX
Shares Outstanding 212.83M
Market Cap 53.21M
EPS -0.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Provectus Biopharmaceuticals, Inc. Receives Patent From USPTO Related To Rose Bengal Analogs

Provectus Biopharmaceuticals, Inc. Receives Patent From USPTO Related To Rose Bengal Analogs

Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT, www.

Provectus Biopharmaceuticals, Inc. Reports Second Quarter 2016 Financial Results

Provectus Biopharmaceuticals, Inc. Reports Second Quarter 2016 Financial Results

Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT, www.

Provectus Biopharmaceuticals Establishes Australian Subsidiary

Provectus Biopharmaceuticals Establishes Australian Subsidiary

Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT, www.

Provectus Biopharmaceuticals Announces PV-10 Data Discussed At 6th European Post-Chicago Melanoma/Skin Cancer Meeting

Provectus Biopharmaceuticals Announces PV-10 Data Discussed At 6th European Post-Chicago Melanoma/Skin Cancer Meeting

Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT, www.

Provectus Biopharmaceuticals Will Present At 2016 BIO International Convention In San Francisco, CA

Provectus Biopharmaceuticals Will Present At 2016 BIO International Convention In San Francisco, CA

Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT, www.

Provectus Biopharmaceuticals Launches Newly Redesigned Website And Official Facebook Page

Provectus Biopharmaceuticals Launches Newly Redesigned Website And Official Facebook Page

Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT, www.

Provectus Biopharmaceuticals Announces Abstract Available On PV-10 Plus Radiotherapy In Melanoma

Provectus Biopharmaceuticals Announces Abstract Available On PV-10 Plus Radiotherapy In Melanoma

Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT, www.

Provectus Biopharmaceuticals, Inc. Reports First Quarter 2016 Financial Results

Provectus Biopharmaceuticals, Inc. Reports First Quarter 2016 Financial Results

Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT) ( www.

Provectus Biopharmaceuticals Reports Trials In Progress Abstract Accepted For Poster Presentation At ASCO Annual Meeting

Provectus Biopharmaceuticals Reports Trials In Progress Abstract Accepted For Poster Presentation At ASCO Annual Meeting

Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT, www.

This Drug Company Loaned Its Now-Fired CEO $2.5M for Made-Up Travel 'Advances'

This Drug Company Loaned Its Now-Fired CEO $2.5M for Made-Up Travel 'Advances'

The extravagant travel-expense payouts to Provectus CEO Craig leaves the company at risk of criminal or civil investigations by the Securities and Exchange Commission.

Provectus Biopharmaceuticals, Inc. Reports Fourth Quarter And Year End 2015 Financial Results

Provectus Biopharmaceuticals, Inc. Reports Fourth Quarter And Year End 2015 Financial Results

Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT, www.

Provectus Announces Results Of Internal Investigation

Provectus Announces Results Of Internal Investigation

Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT) ("Provectus" or the "Company") announced today that the Audit Committee of its Board of Directors (the "Committee") has conducted an internal investigation that was...